Javier Sabater Abad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Javier Sabater Abad has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
María Matellanes‐Palacios
Dermatology Department Hospital Arnau de Vilanova Valencia Spain
4 shared publicationsMaría Matellanes-Palacios
Department of Dermatology, Hospital Arnau de Vilanova, Valencia, Spain
3 shared publications- Andrea Estébanez
Department of Dermatology Hospital Universitario Doctor Peset Valencia Spain
2 shared publications - Andrés Casanova Esquembre
Departamento de Dermatología, Consorcio Hospital General Universitario de Valencia, España
2 shared publications - Carlos Abril‐Pérez
Dermatology Department Hospital Universitario y Politécnico la Fe València Spain
2 shared publications - Edwige Petit
Department of Dermatology, Hospital Arnau de Vilanova, Valencia, Spain
2 shared publications
Latest Publications
- Open Access
- 30 May 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 100 (3) , 566-569
Eficácia e segurança em médio prazo e potenciais preditores de resposta ao upadacitinibe em pacientes com dermatite atópica moderada a grave: estudo retrospectivo observacional multicêntrico
- 30 May 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 100 (3) , 566-569
Open AccessEficácia e segurança em médio prazo e potenciais preditores de resposta ao upadacitinibe em pacientes com dermatite atópica moderada a grave: estudo retrospectivo observacional multicêntrico
- Open Access
- 21 April 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 100 (3) , 566-569
Mid-term effectiveness, safety, and potential predictors of response of upadacitinib in patients with moderate-to-severe atopic dermatitis: a multicenter observational retrospective study
- 21 April 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 100 (3) , 566-569
Open AccessMid-term effectiveness, safety, and potential predictors of response of upadacitinib in patients with moderate-to-severe atopic dermatitis: a multicenter observational retrospective study
- Open Access
- 14 June 2022
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 113 (7) , T740-T741
[Translated article] Primary Cutaneous Cribriform Carcinoma
- 14 June 2022
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 113 (7) , T740-T741
Open Access[Translated article] Primary Cutaneous Cribriform Carcinoma
- 21 September 2020
- Published by Wiley in International Journal of Dermatology
- Vol. 60 (6) , E219-E221
Urticarial and livedoid lesions in a 45‐year‐old woman
- 21 September 2020
- Published by Wiley in International Journal of Dermatology
- Vol. 60 (6) , E219-E221
Urticarial and livedoid lesions in a 45‐year‐old woman
- 18 August 2020
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 62 (1) , E134-E136
Necrotising lymphadenitis resembling Kikuchi‐Fujimoto disease in a patient receiving treatment with risankizumab
- 18 August 2020
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 62 (1) , E134-E136
Necrotising lymphadenitis resembling Kikuchi‐Fujimoto disease in a patient receiving treatment with risankizumab
- 23 June 2020
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 61 (4) , E456-E458
Multiple lesions of cutaneous focal mucinosis in a patient receiving treatment with tocilizumab: Coincidence or causality?
- 23 June 2020
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 61 (4) , E456-E458
Multiple lesions of cutaneous focal mucinosis in a patient receiving treatment with tocilizumab: Coincidence or causality?
- 3 April 2020
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 33 (3) , e13369
Efficacy and safety of adalimumab 80 mg in the treatment of psoriasis: a bicentric retrospective study
Adalimumab (ADA) is a recombinant human monoclonal antibody indicated for the treatment of psoriasis that specifically inhibits tumor necrosis factor. Until recently we only had the presentation of 40 mg of ADA, being the standard dose in adults an initial administration of 80 mg, followed by 40 mg every 2 weeks. Newly the presentation of 80 mg of ADA has been commercialized, allowing the administration of the standard dose or a higher dose, with fewer injections. In this study, we retrospectively studied 11 patients with psoriasis who have received treatment with the presentation of 80 mg of ADA in two dermatology departments of two hospitals in Spain since its commercialization until June 2019. At the end of the study, an improvement in the mean final PASI (Psoriasis Area Severity Index) of all patients was observed, without any patient presenting any adverse effects. This study shows the efficacy and safety of 80 mg of ADA in a sample of 11 patients with psoriasis.
- 3 April 2020
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 33 (3) , e13369
Efficacy and safety of adalimumab 80 mg in the treatment of psoriasis: a bicentric retrospective study
Adalimumab (ADA) is a recombinant human monoclonal antibody indicated for the treatment of psoriasis that specifically inhibits tumor necrosis factor. Until recently we only had the presentation of 40 mg of ADA, being the standard dose in adults an initial administration of 80 mg, followed by 40 mg every 2 weeks. Newly the presentation of 80 mg of ADA has been commercialized, allowing the administration of the standard dose or a higher dose, with fewer injections. In this study, we retrospectively studied 11 patients with psoriasis who have received treatment with the presentation of 80 mg of ADA in two dermatology departments of two hospitals in Spain since its commercialization until June 2019. At the end of the study, an improvement in the mean final PASI (Psoriasis Area Severity Index) of all patients was observed, without any patient presenting any adverse effects. This study shows the efficacy and safety of 80 mg of ADA in a sample of 11 patients with psoriasis.
- Open Access
- 1 January 2020
- Published by California Digital Library (CDL) in Dermatology Online Journal
- Vol. 26 (8)
Giant pilomatrixoma: a distinctive clinical variant: a new case and review of the literature.
Pilomatrixoma is a benign adnexal tumor very common in pediatric age and in young adults that derives from follicular matrix cells. Although clinically it usually presents as a subcutaneous nodule of bluish color less than 3cm in size, multiple clinicopathological variants have been described in the literature. Among these we can find the giant pilomatrixoma, a rare clinical variant that reaches a size greater than or equal to 4cm and can simulate the clinical presentation of a malignant neoplasm. We report a 59-year-old man with an exophytic and ulcerated nodule in the left parotid region that was removed with the suspected diagnosis of a cutaneous squamous cell carcinoma. Histopathological analysis showed a proliferation of basaloid cells with areas of transition to ghost cells, under granulation tissue, hemorrhage, and an ulcerated epidermis. Thus, the diagnosis of giant pilomatrixoma was made. We reviewed the literature and found a total of 53 articles that report a total of 71 cases of giant pilomatrixoma. It is important to recognize this clinical subtype of pilomatrixoma because, apart from the possibility of being clinically confused with malignant lesions, the clinicopathological differential diagnosis must be made with the proliferating pilomatrixoma and pilomatrixcarcinoma.
- 1 January 2020
- Published by California Digital Library (CDL) in Dermatology Online Journal
- Vol. 26 (8)
Open AccessGiant pilomatrixoma: a distinctive clinical variant: a new case and review of the literature.
Pilomatrixoma is a benign adnexal tumor very common in pediatric age and in young adults that derives from follicular matrix cells. Although clinically it usually presents as a subcutaneous nodule of bluish color less than 3cm in size, multiple clinicopathological variants have been described in the literature. Among these we can find the giant pilomatrixoma, a rare clinical variant that reaches a size greater than or equal to 4cm and can simulate the clinical presentation of a malignant neoplasm. We report a 59-year-old man with an exophytic and ulcerated nodule in the left parotid region that was removed with the suspected diagnosis of a cutaneous squamous cell carcinoma. Histopathological analysis showed a proliferation of basaloid cells with areas of transition to ghost cells, under granulation tissue, hemorrhage, and an ulcerated epidermis. Thus, the diagnosis of giant pilomatrixoma was made. We reviewed the literature and found a total of 53 articles that report a total of 71 cases of giant pilomatrixoma. It is important to recognize this clinical subtype of pilomatrixoma because, apart from the possibility of being clinically confused with malignant lesions, the clinicopathological differential diagnosis must be made with the proliferating pilomatrixoma and pilomatrixcarcinoma.
- 1 January 2020
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 82 (1) , e5-e6
Delayed cutaneous knot for closing defects located in the retroauricular fold
- 1 January 2020
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 82 (1) , e5-e6
Delayed cutaneous knot for closing defects located in the retroauricular fold
- 1 August 2019
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 155 (8) , 977-979
Oral Ulcer—A Disabling Manifestation in a Patient With Lipoid Proteinosis
This case report describes a patient who developed lipoid proteinosis with a disabling lingual ulcer that was treated with oral corticosteroids.
- 1 August 2019
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 155 (8) , 977-979
Oral Ulcer—A Disabling Manifestation in a Patient With Lipoid Proteinosis
This case report describes a patient who developed lipoid proteinosis with a disabling lingual ulcer that was treated with oral corticosteroids.